HanchorBio Presents Promising Data on HCB101 Checkpoint Inhibitor Immunotherapy at ASCO

Interim data on the cancer treatment shows robust potential for balancing efficacy and safety TAIPEI and SHANGHAI and SAN FRANCISCO, June 17, 2025 /PRNewswire/ -- Following a successful launch of Phase 2 clinical trials in March, HanchorBio Inc., a...